ES2033574A1 - Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica. - Google Patents

Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica.

Info

Publication number
ES2033574A1
ES2033574A1 ES919101157A ES9101157A ES2033574A1 ES 2033574 A1 ES2033574 A1 ES 2033574A1 ES 919101157 A ES919101157 A ES 919101157A ES 9101157 A ES9101157 A ES 9101157A ES 2033574 A1 ES2033574 A1 ES 2033574A1
Authority
ES
Spain
Prior art keywords
compound
furopyridine
enantiomers
resolution
synthetic precursors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES919101157A
Other languages
English (en)
Other versions
ES2033574B1 (es
Inventor
Charles R Eck
Paul C Shrens
Rae Marie Saltzstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of ES2033574A1 publication Critical patent/ES2033574A1/es
Application granted granted Critical
Publication of ES2033574B1 publication Critical patent/ES2033574B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UN METODO PARA LA PREPARACION DE DERIVADOS DE FURO[3,4-C]PIRIDINA EN UNA FORMA NO RACEMICA, DE FORMULA FORMULA Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE R3,R''3,R4 Y R6 REPRESENTAN DIVERSOS SUBSTITUYENTES, COMPRENDIENDO DICHO METODO RESOLVER UNA MEZCLA RACEMICA DE UNO DE LOS COMPUESTOS DE LAS FORMULAS (2) Y (3) EN DONDE R3,R''3,R4 Y R6 SON COMO SE HAN DEFINIDO ANTERIORMENTE Y R7 REPRESENTA UN GRUPO ACILO DE HASTA C18, SOMETIENDO EL COMPUESTO SELECCIONADO A LA ACCION DE UNA ESTERASA CAPAZ DE HIDROLIZAR LA FORMA ENANTIOMERA (+) O LA FORMA ENANTIOMERA (-) DEL COMPUESTO SELECCIONADO Y SEPARANDO DESPUES LOS COMPUESTOS SIN HIDROLIZAR E HIDROLIZADO. LOS DERIVADOS PREPARADOS TIENEN ACTIVIDADES TERAPEUTICAS DIVERSAS.
ES9101157A 1990-05-14 1991-05-13 Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica. Expired - Fee Related ES2033574B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/523,238 US5130252A (en) 1990-05-14 1990-05-14 Resolution of furopyridine enantiomers and synthetic precursors thereof

Publications (2)

Publication Number Publication Date
ES2033574A1 true ES2033574A1 (es) 1993-03-16
ES2033574B1 ES2033574B1 (es) 1994-02-01

Family

ID=24084213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9101157A Expired - Fee Related ES2033574B1 (es) 1990-05-14 1991-05-13 Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica.

Country Status (32)

Country Link
US (1) US5130252A (es)
JP (1) JPH05117277A (es)
KR (1) KR910020015A (es)
AR (1) AR247762A1 (es)
AT (1) AT400445B (es)
AU (1) AU642368B2 (es)
BE (1) BE1007016A3 (es)
CA (1) CA2042421C (es)
CH (1) CH682488A5 (es)
DE (1) DE4115681C2 (es)
DK (1) DK88991A (es)
DZ (1) DZ1499A1 (es)
ES (1) ES2033574B1 (es)
FI (1) FI97807C (es)
FR (1) FR2661919B1 (es)
GB (1) GB2244056B (es)
GR (1) GR1001593B (es)
HK (1) HK131993A (es)
IE (1) IE65891B1 (es)
IT (1) IT1248743B (es)
LU (1) LU87935A1 (es)
MA (1) MA22154A1 (es)
MY (1) MY107567A (es)
NL (1) NL194615C (es)
NO (1) NO180308C (es)
NZ (1) NZ238009A (es)
OA (1) OA09352A (es)
PT (1) PT97657B (es)
SE (1) SE510808C2 (es)
TN (1) TNSN91035A1 (es)
TW (1) TW226998B (es)
ZA (1) ZA913461B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221494D0 (en) * 2002-09-16 2002-10-23 Generics Uk Ltd Novel processes for the preparation of 1.3-dihydro-6-methylfuro (3,4-c) pyndin derivatives
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US20110251396A1 (en) * 2003-07-17 2011-10-13 Gilead Sciences, Inc. Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2005009446A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
WO2006072172A1 (en) * 2005-01-05 2006-07-13 Medicure International Inc. Compounds and methods for regulating triglyceride levels
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
JP2010514841A (ja) * 2007-01-03 2010-05-06 グレン ブイ． コルネット， 肺疾患および心疾患の処置におけるシクレタニンおよびｐｋｃ阻害剤
US8354394B2 (en) 2009-10-29 2013-01-15 Merck Sharp & Dohme Corp. Diuretics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337858A1 (fr) * 1988-04-06 1989-10-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Procédé stéréospécifique pour la préparation des enantiomères de la furo[3,4-c]pyridine, composés ainsi obtenus et compositions thérapeutiques à base de ces composés
EP0343714A1 (en) * 1988-05-20 1989-11-29 Dsm N.V. Phenylglycidate stereoisomers, conversion products thereof with e.g. 2-nitrothiophenol and preparation of diltiazem
FR2650278A1 (fr) * 1989-07-27 1991-02-01 Scras Procede de preparation de formes non racemiques de derives de la furo (3,4-c) pyridine, composes ainsi obtenus et compositions therapeutiques en contenant

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN156817B (es) * 1981-02-10 1985-11-09 Scras
US4985365A (en) * 1981-11-28 1991-01-15 Sumitomo Chemical Company, Ltd. Process for producing optically active benzyl alcohol compound
EP0101076B1 (en) * 1982-08-13 1989-01-04 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for production of optically active oxazolidinone derivative
IN160104B (es) * 1983-04-05 1987-06-27 Scras
JPS59216590A (ja) * 1983-05-24 1984-12-06 Ube Ind Ltd 光学活性フエニルプロパルギルアルコ−ル誘導体の製法
GB8327817D0 (en) * 1983-10-18 1983-11-16 Scras 4-halo-furo-(3 4-c)-pyridine derivatives
GB8330517D0 (en) * 1983-11-16 1983-12-21 Scras 6-vinyl-furo-(3,4-c)pyridine derivatives
GB8330658D0 (en) * 1983-11-17 1983-12-29 Scras 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives
GB8402740D0 (en) * 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS60224494A (ja) * 1984-04-24 1985-11-08 Nissan Chem Ind Ltd α−メチルベンジルアルコ−ル類の光学分割法
GB8414559D0 (en) * 1984-06-07 1984-07-11 Scras Pyridine derivatives
GB8427218D0 (en) * 1984-10-27 1984-12-05 Scras Pyridine derivatives
JPS61289899A (ja) * 1985-06-18 1986-12-19 Kanegafuchi Chem Ind Co Ltd 光学活性２−ハロ−１−フエニルエタノ−ルおよびそのエステルの製造法
US4916074A (en) * 1986-10-30 1990-04-10 Chisso Corporation Process for producing optically active compounds
JP2691986B2 (ja) * 1987-08-28 1997-12-17 チッソ株式会社 ピリジン骨格を有する光学活性化合物の製造法
DE3737335A1 (de) * 1987-11-04 1989-05-18 Basf Ag Verfahren zur herstellung eines biokatalysators und dessen verwendung zur razematspaltung
DE3990349T1 (de) * 1988-04-06 1990-04-26 Scras Stereospezifisches verfahren zur herstellung von enantiomeren von furo(3,4-c)pyridin, so erhaltene verbindungen und therapeutische zusammensetzungen auf basis dieser verbindungen
GB8907480D0 (en) * 1989-04-03 1989-05-17 Scaras Societe De Conseils De Separation of insomers of furo(3,4-c)pyridine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337858A1 (fr) * 1988-04-06 1989-10-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Procédé stéréospécifique pour la préparation des enantiomères de la furo[3,4-c]pyridine, composés ainsi obtenus et compositions thérapeutiques à base de ces composés
EP0343714A1 (en) * 1988-05-20 1989-11-29 Dsm N.V. Phenylglycidate stereoisomers, conversion products thereof with e.g. 2-nitrothiophenol and preparation of diltiazem
FR2650278A1 (fr) * 1989-07-27 1991-02-01 Scras Procede de preparation de formes non racemiques de derives de la furo (3,4-c) pyridine, composes ainsi obtenus et compositions therapeutiques en contenant

Also Published As

Publication number Publication date
AU7620091A (en) 1991-11-14
KR910020015A (ko) 1991-12-19
PT97657A (pt) 1992-02-28
NL194615B (nl) 2002-05-01
CA2042421A1 (en) 1991-11-15
DZ1499A1 (fr) 2004-09-13
US5130252A (en) 1992-07-14
TW226998B (es) 1994-07-21
FI97807B (fi) 1996-11-15
AR247762A1 (es) 1995-03-31
AT400445B (de) 1995-12-27
GB2244056B (en) 1993-08-11
DE4115681C2 (de) 2003-10-30
LU87935A1 (fr) 1992-03-03
SE510808C2 (sv) 1999-06-28
DK88991A (da) 1991-11-15
MY107567A (en) 1996-04-30
CH682488A5 (fr) 1993-09-30
MA22154A1 (fr) 1991-12-31
AU642368B2 (en) 1993-10-14
GR910100180A (en) 1992-07-30
NZ238009A (en) 1992-11-25
GR1001593B (el) 1993-03-31
IE911628A1 (en) 1991-11-20
NO180308C (no) 1997-03-26
OA09352A (fr) 1992-09-15
NL9100749A (nl) 1991-12-02
ZA913461B (en) 1992-02-26
NO911852L (no) 1991-11-15
FI97807C (fi) 1997-02-25
ITMI911255A0 (it) 1991-05-08
TNSN91035A1 (fr) 1992-10-25
DE4115681A1 (de) 1991-11-21
ATA98291A (de) 1995-05-15
FR2661919B1 (fr) 1994-12-30
NL194615C (nl) 2002-09-03
DK88991D0 (da) 1991-05-13
HK131993A (en) 1993-12-10
CA2042421C (en) 2000-08-22
PT97657B (pt) 1998-09-30
JPH05117277A (ja) 1993-05-14
IE65891B1 (en) 1995-11-29
BE1007016A3 (fr) 1995-02-21
NO911852D0 (no) 1991-05-13
SE9101431L (sv) 1991-11-15
GB9109810D0 (en) 1991-06-26
FR2661919A1 (fr) 1991-11-15
ITMI911255A1 (it) 1992-11-08
ES2033574B1 (es) 1994-02-01
FI912315A0 (fi) 1991-05-13
SE9101431D0 (sv) 1991-05-13
IT1248743B (it) 1995-01-26
FI912315A (fi) 1991-11-15
NO180308B (no) 1996-12-16
GB2244056A (en) 1991-11-20

Similar Documents

Publication Publication Date Title
ES2033574A1 (es) Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica.
ATE40570T1 (de) Verfahren zur herstellung eines optisch aktiven 3-(3,4-dihydroxyphenyl)-serins und ein geschuetztes derivat davon.
FI20001108A (fi) Menetelmä raseemisen cis-yhdisteen valmistamiseksi
MY110188A (en) Process for stereospecific hydrolisit of piperidinediene derivatives
JPS5794295A (en) Preparation of optically active ester and/or acid
ES8604581A1 (es) Procedimiento para la preparacion de derivados cis hidroxiiminooctahidroindolo(2,3-a)quinolizina racemicos
ATE19394T1 (de) Verfahren zur herstellung von cyclopropancarbonsaeureesterderivaten.
ATE126230T1 (de) Cephalosporinderivate und verfahren zur herstellung von cephem-verbindungen.
DE69520368D1 (de) Verfahren zur herstellung von 5-hydroxymethyl-thiazole
ES8706705A1 (es) Procedimiento para la resolucion optica de mezclas racemicas de acidos alfa-naftilpropionicos
DE3576152D1 (de) Verfahren zur optischen auftrennung racemischer gemische von alpha-naphthylpropionsaeuren.
IE820220L (en) Amino protected asp-phe alkyl ester
TW341559B (en) Process for racemization of optically active 1-phenylethylamine derivative
PL323817A1 (en) Method of transforming 2,4-dichloropyridines into 2-aryloxy-4-chloropyridines
IL108829A0 (en) Enzymatic resolution of alkyl 2-piperidinecarboxylates and use of the compounds obtained as synthesis intermediates
DE3578423D1 (de) Neue cephalosporine und verfahren zu ihrer herstellung.
DE3585154D1 (de) Verfahren zur herstellung von cephalosporinestern.
ES8504710A1 (es) Procedimiento para la resolucion optica de una mezcla de enantiomeros de un derivados de piperidina.
AU585703B2 (en) Process for the enzymatic resolution of racemic 2-amino- 1-alkanols
EP0158226A3 (en) Method of synthesizing esters
EP0204481A3 (en) Process for optically active threo-3-(3,4-methylenedioxyphenyl) serine
EP0795609A3 (en) Process for preparing optically active trans-3-phenylglycidamide compounds
KR880009898A (ko) (r)-2-하이드록시-4-페닐부티르산 및 에스테르의 제조 및 분리방법
AU7581696A (en) Preparation of chiral 3-hydroxy-2-pyrrolidinone derivatives
EP0128027A3 (en) Cephalosporin esters, their production and use

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20041102